Pancreatic Cancer Research

ResearcherInsermActive in the last 2 years

Franck Bonnetain

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5064556770. Sources: OpenAlex.

Their work

Papers
19 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
93
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: 4 papers · 2016: 4 papers · 2017: 3 papers · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 19

  1. Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study. Co-author DOI 10.1093/oncolo/oyaf125↗
  2. Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leu… Last author DOI 10.1002/cam4.2311↗
  3. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Co-author DOI 10.1016/s1470-2045(18)30098-6↗
  4. Care pathway of patients with metastatic pancreatic cancer in daily practice in France: Results from the REPERE national survey. Last author DOI 10.1016/j.bulcan.2016.11.022↗
  5. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR)… Co-author DOI 10.1016/s2468-1253(17)30046-8↗
  6. Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1093/jnci/djx037↗
  7. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Wi… Co-author DOI 10.1001/jama.2016.4324↗
  8. Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology. Last author DOI 10.1007/s11136-015-1198-x↗
  9. Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP). Last author DOI 10.1038/bjc.2016.212↗
  10. Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a mu… Co-author DOI 10.1186/s12885-016-2860-6↗
  11. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Co-author DOI 10.1038/bjc.2015.328↗
  12. A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer:… Co-author DOI 10.1186/s12885-015-1656-4↗
  13. Rationale and design of the Adapted Physical Activity in advanced Pancreatic Cancer patients (APACaP) GERCOR (Groupe Coopérateur Multidisciplinaire en Oncologi… Co-author DOI 10.1186/s13063-015-0983-8↗
  14. Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A… Last author DOI 10.1371/journal.pone.0125350↗
  15. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to… Co-author DOI 10.1016/j.ejca.2014.07.011↗
  16. Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastat… Co-author DOI 10.1016/j.ejca.2014.09.015↗
  17. S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ejca.2013.04.017↗
  18. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. Co-author DOI 10.1093/annonc/mdr617↗
  19. [Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results … Co-author DOI 10.1016/j.canrad.2010.10.001↗

Closest collaborators

The 25 strongest of 93 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Pascal R. Hammel · 13 shared papers, 2011–2025 · strength 0.73
  2. Julien Taı̈eb · 9 shared papers, 2014–2025 · strength 0.53
  3. Jean‐Baptiste Bachet · 7 shared papers, 2012–2025 · strength 0.44
  4. Christophe Louvet · 8 shared papers, 2012–2019 · strength 0.39
  5. Romain Coriat · 3 shared papers, 2015–2025 · strength 0.28
  6. Thierry André · 6 shared papers, 2012–2017 · strength 0.26
  7. Anne‐Laure Pointet · 3 shared papers, 2016–2025 · strength 0.25
  8. Isabelle Trouilloud · 3 shared papers, 2014–2025 · strength 0.24
  9. Laëtitia Dahan · 3 shared papers, 2014–2025 · strength 0.23
  10. Jean‐Luc Van Laethem · 5 shared papers, 2012–2018 · strength 0.20
  11. Alix Portal · 2 shared papers, 2015–2025 · strength 0.20
  12. Lysiane Marthey · 2 shared papers, 2015–2025 · strength 0.20
  13. Simon Pernot · 2 shared papers, 2015–2025 · strength 0.20
  14. David Tougeron · 2 shared papers, 2015–2025 · strength 0.20
  15. Christophe Tournigand · 3 shared papers, 2017–2019 · strength 0.18
  16. Bengt L. G. Glimelius · 4 shared papers, 2014–2018 · strength 0.18
  17. Raëf Abdallah · 1 shared paper, 2025 · strength 0.16
  18. Jean–Marc Phelip · 1 shared paper, 2025 · strength 0.16
  19. Camille Evrard · 1 shared paper, 2025 · strength 0.16
  20. Émilie Soularue · 1 shared paper, 2025 · strength 0.16
  21. Dominique Béchade · 1 shared paper, 2025 · strength 0.16
  22. Nicolas Williet · 1 shared paper, 2025 · strength 0.16
  23. David Goldstein · 3 shared papers, 2016–2018 · strength 0.15
  24. Déwi Vernerey · 3 shared papers, 2016–2017 · strength 0.15
  25. P. Debourdeau · 2 shared papers, 2017–2019 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.